Ocugen Inc.

07/25/2024 | Press release | Distributed by Public on 07/25/2024 05:42

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.